Prevention & lipidsResearch article
Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition
- Narrative review
Authors' conclusion
ACLY inhibition with bempedoic acid has been established as a safe and effective therapy in high-risk patients who require further LDL-C lowering, particularly for those with a history of statin intolerance.
Main finding
As reported in the abstract
CLEAR Outcomes primary 4-way CV composite end point
- Bempedoic acid modestly reduced the primary 4-way CV composite end point and MI and coronary revascularization
- No reduction in stroke, CV death or all-cause mortality
Safety
Gout, cholelithiasis, serum creatinine, uric acid, hepatic enzymes
- Higher rates of gout and cholelithiasis and small increases in serum creatinine, uric acid and hepatic-enzyme levels with bempedoic acid
Original publication
Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition. JAMA Cardiol. Published 1 September 2023. doi:10.1001/jamacardio.2023.2402
Summarised from the published abstract; every number is checked against it